There are currently 48 clinical trials in Irving, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University Hills Clinical Research, Pfizer Investigational Site, Novo Nordisk Investigational Site and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
NCT05975073
Recruiting
The main aims of this study are to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or the recommended combination dose of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null solid tumors, and to evaluate the preliminary anti-tumor activity of AMG 193 in combination with IDE397 in adult participants with metastatic or locally advanced MTAP-null Non-Small-Cell Lung Cancer (NSCLC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: Next Oncology, Irving, Texas
Conditions: MTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid Tumors
Register for Updates
A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis
NCT05437263
Recruiting
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with dermatomyositis (DM). The primary objective of this study is to assess the efficacy of two dose levels of brepocitinib in comparison to placebo, as measured by differences in the Total Improvement Score (TIS). After 52 weeks of double-blind treatment, participants have the option to continue therapy in a 52 week open-label extension phase where al... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/19/2024
Locations: Clinical Trial Site, Irving, Texas
Conditions: Dermatomyositis
Register for Updates
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
NCT06345339
Recruiting
This study will evaluate the efficacy and safety of Armour Thyroid treatment compared with synthetic T4 in subjects who have primary hypothyroidism and are currently stabilized (i.e., in-range thyroid-stimulating hormone [TSH]) on synthetic T4 treatment. This study will also therefore evaluate the efficacy and safety of dose conversion from synthetic T4 therapy to Armour Thyroid therapy.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2024
Locations: Tekton Research /ID# 260988, Irving, Texas
Conditions: Hypothyroidism
Register for Updates
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
NCT05026866
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 65 years and 80 years
Trial Updated:
06/17/2024
Locations: Optum Infusion - Irving, Irving, Texas
Conditions: Alzheimer Disease
Register for Updates
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus
NCT05039840
Recruiting
This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in the treatment of participants aged 18 to 70 years with active Systemic Lupus Erythematosus (SLE). Study details include: Study duration: 36 weeks Treatment duration: 24 weeks Visit frequency: every 2 weeks
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/17/2024
Locations: Lone Star Arthritis & Rheumatology Associates Site Number : 8400024, Irving, Texas
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
NCT05145413
Recruiting
This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequate response to their current atypical antipsychotic treatment. The primary objective of the study is to assess the efficacy of adjunctive KarXT (a fixed dose combination of xanomeline and trospium chloride twice daily [BID]) versus placebo in the treatment of subjects with inadequately controlled symptoms of schizophrenia as measured by the Positiv... Read More
Gender:
All
Ages:
Between 18 years and 59 years
Trial Updated:
06/17/2024
Locations: Clinical Trial Site, Irving, Texas
Conditions: Schizophrenia
Register for Updates
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
NCT05954312
Recruiting
A FIH study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of VVD-130037 in participants with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: NEXT Dallas, Irving, Texas
Conditions: Advanced Solid Tumors
Register for Updates
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors
NCT06188208
Recruiting
A FIH study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of VVD-130850, as single agent and in combination with checkpoint inhibition, in participants with advanced solid and hematologic tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: NEXT Dallas, Irving, Texas
Conditions: Advanced Solid Tumors, Advanced Hematologic Tumors
Register for Updates
Study of APR-1051 in Patients With Advanced Solid Tumors
NCT06260514
Recruiting
The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: NEXT Oncology -Dallas, Irving, Texas
Conditions: Advanced Solid Tumor
Register for Updates
Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551
Recruiting
This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.
Gender:
All
Ages:
Between 18 years and 125 years
Trial Updated:
06/13/2024
Locations: NEXT Dallas, Irving, Texas
Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Register for Updates
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
NCT00781612
Recruiting
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: US Oncology Research Pharm., Irving, Texas +1 locations
Conditions: Neoplasm Metastasis
Register for Updates
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
NCT06334432
Recruiting
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: NEXT Oncology, Irving, Texas
Conditions: Advanced Solid Tumor, HER2-negative Breast Cancer, Metastatic Castration-resistant Prostate Cancer (mCRPC), Pancreatic Cancer, Platinum-resistant Ovarian Cancer (PROC)
Register for Updates